

July 2017 APC Decisions

Medicine	Classification	Indication	Other Information
Sucroferric oxyhydroxide (Velporo®)	RED	Phosphate binder in patients with CKD on dialysis	To be added to the existing Shared Care protocol as a second line non-calcium channel based phosphate binder. Only for patients who cannot tolerate sevelamer. To be amended to AMBER 1 following update of the Shared Care documents
FIASP® (Faster acting insulin aspart)	AMBER 2	Diabetes	For use where tighter control is required. Can be given 20 minutes from starting a meal

For a full explanation of the Traffic Light definitions, please refer to the [Joint Formulary website](#)

News from the APC

New to the APC website

- [DMARD Shared Care Protocols for Rheumatology \(Update\)](#)
- [Laxative treatment \(Update\)](#)
- [Antimicrobial Guideline \(Update\)](#) and [Quick Reference Guide](#)

Coming soon to the APC website

- *Management of hyperlipidaemia and hypertriglyceridaemia (New)*
- *Ocular lubricants formulary (new)*
- *Sip feeds guidelines (update)*

Error in guideline

It has come to our attention that there has been an error in the Primary Care Management of Nausea and Vomiting In Early Pregnancy Guideline. The dose of promethazine was incorrect and has now been updated to **25mg ON, up to 25mg QDS**. Although the maximum daily dose which was incorrectly quoted was stated within some papers, it was not the usual recommended dose which would be in line with current reference sources .

NHS.net e mail

We have migrated to NHS.net e mail. Our new e mail address is:

MACCG.NottsAPC@nhs.net

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments

- Neocate Junior is the new product name to replace Neocate Active which will be discontinued in 2018
- Due to a supply issue with Phosex® , Renacet ® has been added to the formulary and the shared care protocol as a suitable alternative
- Ellest Solo-MX reclassified to **GREEN** in line with other HRT options

Current work in development

- Review of the Triptan formulary chapter
- Glucodrate® rehydration solution (New submission)
- Colestipol for bile acid secretions (Evidence review)
- Roflumilast for COPD (NICE TA)
- Melatonin for MS (New submission)
- Chlortalidone for hypertension (New submission)
- Colesevelam for hypercholesterolemia (New submission)
- Methoxyflurane for pain relief (New submission)
- Update of formulary vaccines against national guidelines
- Emollient Formulary (Review)
- Testosterone prescribing and monitoring information (New)
- ADHD management in adults

Upcoming NICE guidance

TITLE	GUIDELINE/TA	EXPECTED DATE
Parkinsons' Disease	Guideline	April 2017 - delayed
Etelcalcetide for treating secondary hyperparathyroidism	Technology Appraisal	June 2017
Hyperuricaemia (chronic) in gout - lesinurad	Technology Appraisal	July 2017
Familial hypercholesterolaemia	Guideline	August 2017
Obesity, overweight with risk factors - naltrexone-bupropion	Technology Appraisal	August 2017
Urinary tract infection in under 16s	Guideline	September 2017
Irritable bowel syndrome (diarrhoea) - eluxadolone	Technology Appraisal	September 2017
Endometriosis: diagnosis and management	Guideline	September 2017
Asthma management	Guideline	October 2017
Asthma diagnosis and monitoring	Guideline	October 2017
Glaucoma: diagnosis and management	Guideline review	October 2017

The work of the NAPC is supported and managed by the interface team below. They can be contacted via MACCG.NottsAPC@nhs.net if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Nick Sherwood, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Lynne Kennel, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust